Supplemental educational content

Chapter 5: Regulation of the Menstrual Cycle – Where to Focus

This chapter reviews menstrual cycle physiology. For fertility‑relevant concepts, readers may wish to focus on:

• Follicular development & ovarian reserve (pp. 139–145): role of FSH, AMH, inhibin, and follicle selection
• FSH/LH coordination (two‑cell, two‑gonadotropin model) (pp. 143–146)
• Dominant follicle selection & estrogen feedback (pp. 144–148)
• Preovulatory follicle, LH surge & ovulation (pp. 155–162)
• Luteal phase & corpus luteum function (pp. 162–166)
• Luteal–follicular transition & FSH rise (pp. 166–168)

Chapter 28: Female Infertility – Where to Focus

This chapter is broad and clinical. For fertility‑relevant concepts, readers may wish to focus on:

• Definitions & timing of evaluation (≈ pp. 1017–1018): infertility vs subfertility; age‑based evaluation thresholds
• Aging & female fertility (≈ pp. 1019–1024): age‑related decline, miscarriage risk, oocyte aneuploidy
• Ovarian reserve & reproductive aging (≈ pp. 1020–1028): follicle depletion, AMH, AFC, FSH; limits of testing
• Ovulatory function & assessment (≈ pp. 1034–1039): regular cycles, progesterone, LH surge, limits of LPD testing
• Tubal factor infertility (≈ pp. 1047–1053): PID risk, HSG vs laparoscopy, hydrosalpinx & IVF outcomes
• Uterine factors (≈ pp. 1040–1046): fibroids, polyps, adhesions; impact on implantation
• Unexplained infertility (≈ pp. 1053–1057): diagnosis of exclusion, age effects, treatment hierarchy
• Treatment overview (≈ pp. 1055–1057): IUI vs IVF; diminishing returns with age

Chapter 30: Induction of Ovulation – Where to Focus

This chapter is long and treatment‑heavy. For fertility‑relevant concepts, readers may wish to focus on:

• Diagnosis of anovulation (≈ pp. 1111–1112): irregular menses as presumptive anovulation; progesterone <3 ng/mL; importance of correct timing (not always day 21)
• WHO classification of ovulatory disorders (≈ pp. 1112–1113): Group I (hypogonadotropic), Group II (normogonadotropic/PCOS), Group III (hypergonadotropic); implications for treatment choice
• Pretreatment evaluation (≈ pp. 1112–1114): TSH, prolactin, metabolic screening in PCOS, semen analysis, when to assess tubal patency
• Lifestyle & weight effects (≈ pp. 1113–1114): 5–10% weight loss restoring ovulation in PCOS; impact on treatment response
• First‑line oral ovulation induction (≈ pp. 1114–1116):
• Letrozole vs clomiphene; higher live birth rates with letrozole in PCOS; dosing principles
• Clomiphene citrate specifics (≈ pp. 1117–1121): mechanism, ovulation vs pregnancy rates, anti‑estrogenic effects, multiple‑gestation risk
• Monitoring ovulation induction (≈ pp. 1121–1122): progesterone confirmation, LH kits, limited role of routine ultrasound in oral agents
• Second‑line therapies (≈ pp. 1122–1125): metformin (adjunct), glucocorticoids, ovarian drilling—when and why
• Gonadotropin therapy (≈ pp. 1126–1132): indications, need for close monitoring, risks of multiple pregnancy and OHSS
• Special causes (≈ pp. 1136–1138): pulsatile GnRH for hypogonadotropic hypogonadism; dopamine agonists for hyperprolactinemia
• Major risks & counseling (≈ pp. 1131–1135): multiple gestation, OHSS, importance of cycle cancellation and patient counseling

Chapter 31: Assisted Reproductive Technologies – Where to Focus

This chapter is very long and procedural. For fertility‑relevant concepts, readers may wish to focus on:

• Definition & scope of ART (≈ pp. 1149–1150): IVF as core ART; role of ICSI, PGT (A/M/SR), donor gametes, gestational surrogacy, fertility preservation
• Indications for IVF (≈ pp. 1149–1153): severe tubal disease, hydrosalpinx, severe male factor, multifactor infertility, unexplained infertility, age‑related infertility, diminished ovarian reserve, uterine factor, genetic risk
• Tubal factor & hydrosalpinx (≈ pp. 1150–1151): hydrosalpinges ↓ IVF success ~50%; salpingectomy or proximal occlusion before IVF improves live birth rates
• Male factor infertility & ART (≈ pp. 1151–1152): ICSI indications (severe oligospermia, poor motility/morphology, surgically retrieved sperm); limits of IUI; genetics in severe cases
• Endometriosis & IVF (≈ pp. 1151–1152): IVF overcomes anatomic factors; endometriomas usually left untreated pre‑IVF; surgery mainly for pain or select prognostic cases
• Unexplained infertility (≈ pp. 1152): IVF most effective treatment; ICSI controversial without male factor
• Diminished ovarian reserve & oocyte donation (≈ pp. 1152–1155): rising indication for ART; AMH/AFC predict response not pregnancy; donor oocytes overcome age‑related oocyte aneuploidy
• Prognostic factors for IVF success (≈ pp. 1153–1156):Maternal age (strongest factor), ovarian reserve, BMI, diagnosis, prior ART outcomes
• Ovarian stimulation principles (≈ pp. 1158–1164): gonadotropins + pituitary suppression (GnRH antagonist most common); individualized dosing debated; OHSS risk
• Triggering ovulation & OHSS prevention (≈ pp. 1165–1166): hCG vs GnRH‑agonist trigger; agonist trigger ↓ OHSS (PCOS, high responders); freeze‑all strategy
• Embryo culture & transfer stage (≈ pp. 1172–1174): cleavage vs blastocyst; blastocyst transfer ↑ implantation, ↓ multiples, ↑ monozygotic twinning
• Embryo transfer technique (≈ pp. 1179–1181): soft catheter + ultrasound guidance improves outcomes; difficult transfer ↓ pregnancy rates
• Number of embryos transferred (≈ pp. 1180–1182): elective single embryo transfer (eSET) standard; ASRM age‑based limits; goal = singleton pregnancy
• Frozen embryo transfer (≈ pp. 1182–1185): vitrification preferred; FET now majority of transfers; natural vs programmed cycles and obstetric implications
• PGT essentials (≈ pp. 1174–1178): PGT‑A reduces miscarriage and multiple gestation per transfer but not cumulative live birth; mosaicism interpretation limits
• Maternal & offspring risks (≈ pp. 1186–1191): ↑ preterm birth, LBW, LGA (esp FET), hypertensive disorders; absolute risks remain low
• Oocyte donation & surrogacy (≈ pp. 1191–1194): donor age—not recipient age—drives success; increased obstetric risk in recipients; indications for gestational carrier

Chapter 20: Female Subfertility

Gain a deeper understanding of female subfertility and the factors influencing reproductive outcomes, including ovarian function, hormonal dynamics, and treatment selection. This chapter emphasizes the importance of tailored ovarian stimulation strategies and the physiologic role of gonadotropins in supporting follicular development and improving the chances of success.

Chapter 23: Assisted Reproductive Technologies

This chapter explores modern ART approaches with a focus on ovarian stimulation strategies and patient-specific protocol selection. It underscores how tailoring gonadotropin use and optimizing hormonal support can play a critical role in maximizing oocyte yield, embryo development, and overall success rates.